Form 4: ResMed Executive Kaushik Ghoshal Executes Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Chief Commercial Officer of ResMed, Kaushik Ghoshal, exercised stock options and sold shares of ResMed common stock under a pre-arranged 10b5-1 trading plan.
Summary
- Kaushik Ghoshal, Chief Commercial Officer, SaaS at ResMed Inc., executed stock options and sold shares of common stock on March 10, 2025.
- The transactions were conducted under a Rule 10b5-1 plan adopted on November 29, 2024.
- Ghoshal exercised options with exercise prices of $146.34 and $211.76.
- He acquired a total of 9,745 shares through option exercises.
- He then sold 9,745 shares at a weighted average price of $239.3121, with prices ranging from $236.62 to $242.73.
- Following these transactions, Ghoshal directly owns 9,725 shares of ResMed common stock and indirectly owns 9,628 shares through the Kaushik Ghoshal and Jayati Ghoshal Family Trust.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't convey any particularly positive or negative sentiment.
Future Outlook
There is no future outlook provided in this document.
Industry Context
This filing is a routine disclosure of insider transactions and doesn't necessarily reflect broader industry trends. It indicates an executive's activity in managing their equity compensation.
Comparison to Industry Standards
- Executive stock option exercises and sales are common in publicly traded companies, particularly in the healthcare and technology sectors.
- The use of 10b5-1 plans is a standard practice to allow insiders to trade company stock without concerns about insider trading violations.
- Comparable companies like Philips and Medtronic also have executives who regularly exercise stock options and sell shares, as disclosed in their SEC filings.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the sale of shares in the open market.
- The impact is likely minimal as the transactions were pre-planned and represent a small portion of the company's outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 11/21/2019 | Date options first become exercisable. |
| 11/19/2020 | Date options first become exercisable. |
| 11/29/2024 | Date the Rule 10b5-1 plan was adopted. |
| 03/10/2025 | Date of the stock option exercise and sale of shares. |
| 03/11/2025 | Date of signature on the Form 4 filing. |
| 11/21/2026 | Expiration date of some stock options. |
| 11/19/2027 | Expiration date of some stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.